Abstract 127: Riboflavin biosynthesis byproducts increase the vulnerability of cancer to adoptive MAIT TCR-engineered T-cell transfer.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institutions: Johns Hopkins University, Stanford Medicine, Stanford University
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148799692
Cites:
Cited by:
Related to: